Articles
Ideas shaping biotechnology growth—commercial leadership, launch strategy, and rare disease insights from PharmaKonsult.
Why Leadership Decisions Determine Commercial Success
Commercial success is rarely determined by the quality of the science alone—it is designed by leaders who make disciplined decisions long before launch.
Read articleCommercial Culture & Leadership
Scientific innovation discovers new possibilities. Leadership and culture determine whether those possibilities change patients' lives.
Read articleWhat Biotechnology Leaders Can Learn from Marinus Pharmaceuticals
A commercialization case study in rare disease strategy—why treated patients, not prevalence estimates, should drive commercial infrastructure and capital allocation.
Read articleBeyond the Science: How CEOs and Investors Should Evaluate Emerging Therapeutic Platforms
Using Sec61 as a case study in commercial decision-making—why the first indication, not the mechanism alone, often determines whether a platform becomes a successful enterprise.
Read articleCAH Is Entering a New Era: Commercial Execution Will Determine the Winner
A clinical, scientific, and commercial review of current CAH therapy, emerging ACTH receptor antagonism, and the market factors likely to determine the next generation of care.
Read articleCushing's Syndrome and Cushing Disease: Treatment Value Begins with the Correct Diagnosis
For Cushing's syndrome, commercial success depends less on competition than on identifying patients early enough to enter the treatment pathway—diagnosis is the first commercial barrier.
Read articleWhy Rare Disease Commercial Forecasts Often Miss Reality
Optimistic rare disease forecasts often overlook commercial friction—diagnosis delays, Centers of Excellence access, reimbursement, and adoption—that shrink the treatable population before launch.
Read articleThe Future of Hiring in Biotechnology
Why great resumes don't always build great organizations—and why collaboration, trust, and organizational fit now matter as much as experience.
Read article